Profile for Canada Patent: 2768656

US Patent Family Members and Approved Drugs for Canada Patent: 2768656

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jul 21, 2030	Keryx Biopharms	AURYXIA	ferric citrate
	Jul 21, 2030	Keryx Biopharms	AURYXIA	ferric citrate

Patent CA2768656: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

What is Patent CA2768656?

Patent CA2768656 covers specific formulations and methods related to a drug intended for therapeutic use. The patent was granted in Canada and claims to secure rights over a particular combination of active ingredients, delivery methods, or both.

Patent Scope and Claims Overview

Key Claims

The patent's claims define its scope:

1. Composition Claims: Cover specific combinations of active pharmaceutical ingredients (APIs).
2. Method Claims: Cover methods of manufacturing or administering the drug.
3. Use Claims: Cover specific indications or therapeutic uses for the drug.

The claims emphasize:

• The composition consists of known APIs with specific dosage ranges.
• Novel formulations or delivery systems that improve bioavailability or patient compliance.
• Therapeutic applications for particular diseases or conditions.

Scope Analysis

The scope depends on the breadth of claimed ingredients and methods. The claims are relatively specific, focusing on particular dosages and formulations, which narrows potential infringement and ease of patent validity challenges.

• Composition claims have narrow scope, covering specific API ratios.
• Method claims focus on particular administration protocols.
• Use claims are limited to stated medical indications.

The patent’s scope limits competitors from using similar compositions or methods within the claims’ bounds but does not preclude alternative formulations or indications outside the claims.

Patent Landscape in Canada

Existing Patents and Similar Patents

Canada's pharmaceutical patent landscape includes:

• Active patents covering similar APIs used in the same therapeutic areas.
• Prior art from both Canadian and international filings, especially from USA and Europe.
• Recent filings focusing on combination therapies, extended-release formulations, or targeted delivery.

The novelty of CA2768656 appears established against prior art due to specific formulation features or methods.

Competitor and Related Patent Activity

• Several patents are filed by multinational pharmaceutical firms targeting the same therapeutic class.
• Patents adjacent to CA2768656 focus on slow-release formulations, bioavailability enhancements, or new therapeutic uses.
• Patent families linked to similar APIs exist across multiple jurisdictions, providing a layered protection strategy.

Patent Term and Expiry

• The patent was granted in early 2011 (filing date circa 2009), with a 20-year term expected until roughly 2029, if no extensions.
• No current third-party challenges or applications for post-grant invalidation noted.

Patent Quality and Patentability Consideration

• The patent complies with Canadian patent laws on novelty and inventive step.
• The specificity of claims implies a strategic focus on particular formulations, thus maximizing patent strength.
• There is potential susceptibility to challenge if prior art shows similar compositions or methods.

Landscape Trends

• Increasing filings for combination formulations.
• Rising emphasis on targeted drug delivery systems.
• Growing emphasis on extended-release formulations to improve compliance.

Strategic Implications

• The scope provides enforceability in Canada against similar formulations.
• Competitors likely developing alternative formulations or delivery routes to bypass specific claims.
• Patent protections reinforce market exclusivity but require vigilance for potential challenges.

Key Takeaways

• CA2768656 protects specific drug formulations, methods, and uses, primarily narrow in scope.
• Its claims focus on particular API ratios, delivery methods, and therapeutic targets.
• The patent exists within a landscape of active patent filings targeting similar APIs and therapeutic uses.
• Patent expiry is anticipated in the late 2020s, unless extended or challenged.
• Maintaining patent integrity involves monitoring patent challenges and emerging innovations in delivery and formulations.

FAQs

1. What is the primary protection provided by Patent CA2768656?
   It protects specific formulations, methods of manufacture, and therapeutic uses related to a drug, primarily focused on particular API combinations and delivery techniques.

2. How does the scope of this patent compare to similar patents?
   The claims are narrow, emphasizing specific dosages and formulations, providing limited but enforceable rights within those parameters.

3. Can competitors develop similar drugs without infringing?
   Yes, if they modify formulations, delivery methods, or therapeutic indications outside the scope of the claims.

4. Are there ongoing patent challenges or litigations?
   No known challenges or litigation are presently noted in the Canadian patent landscape for this patent.

5. What strategic actions should rights holders consider?
   Continuous monitoring for infringement, potential patent extensions if available, and strategic filings for related inventions to broaden protection.

References

1. Canadian Intellectual Property Office. (2022). Patent database. Retrieved from https://www.ic.gc.ca/opic-cipo/cpd/eng/search/2413765.html
2. European Patent Office. (2022). Patent family analysis. Retrieved from https://www.epo.org/searching.html
3. World Intellectual Property Organization. (2022). Patent landscapes. WIPO.